187 related articles for article (PubMed ID: 8619585)
1. In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis.
Hirata T; Saito H; Tomioka H; Sato K; Jidoi J; Hosoe K; Hidaka T
Antimicrob Agents Chemother; 1995 Oct; 39(10):2295-303. PubMed ID: 8619585
[TBL] [Abstract][Full Text] [Related]
2. [In vitro activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis].
Sato K; Tomioka H; Saito H; Kawahara S; Hidaka T
Kekkaku; 1996 Aug; 71(8):459-64. PubMed ID: 8831191
[TBL] [Abstract][Full Text] [Related]
3. [Studies on therapeutic efficacy of a new anti-tuberculous drug, benzoxazinorifamycin, against murine experimental mycobacterial infections: attempt at various regimens and protocols].
Tomioka H; Saito H
Kekkaku; 1994 Nov; 69(11):703-10. PubMed ID: 7837724
[TBL] [Abstract][Full Text] [Related]
4. [Therapeutic efficacy of benzoxazinorifamycin KRM-1648 against experimental murine tuberculosis: (1). A study on the efficacy of short course treatment with the intratracheal and intravenous infection model].
Doi N
Kekkaku; 1998 Feb; 73(2):53-64. PubMed ID: 9545697
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli.
Luna-Herrera J; Reddy MV; Gangadharam PR
Antimicrob Agents Chemother; 1995 Feb; 39(2):440-4. PubMed ID: 7726512
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapeutic activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium tuberculosis in C57BL/6 mice.
Reddy MV; Luna-Herrera J; Daneluzzi D; Gangadharam PR
Tuber Lung Dis; 1996 Apr; 77(2):154-9. PubMed ID: 8762850
[TBL] [Abstract][Full Text] [Related]
7. In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins.
Saito H; Tomioka H; Sato K; Emori M; Yamane T; Yamashita K; Hosoe K; Hidaka T
Antimicrob Agents Chemother; 1991 Mar; 35(3):542-7. PubMed ID: 2039206
[TBL] [Abstract][Full Text] [Related]
8. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis.
Yang B; Koga H; Ohno H; Ogawa K; Fukuda M; Hirakata Y; Maesaki S; Tomono K; Tashiro T; Kohno S
J Antimicrob Chemother; 1998 Nov; 42(5):621-8. PubMed ID: 9848446
[TBL] [Abstract][Full Text] [Related]
9. [Therapeutic efficacy of a benzoxazinorifamycin, KRM-1648, administered at the different periods of infection in Mycobacterium intracellulare--infected mice].
Tomioka H; Sato K; Saito H; Hidaka T
Kekkaku; 1993 Oct; 68(10):631-5. PubMed ID: 8255070
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo activities of KRM-1648, a newly synthesized benzoxazinorifamycin, against Mycobacterium marinum.
Yamamoto Y; Saito H; Tomioka H; Sato K; Yamane T; Yamashita K; Hosoe K; Hidaka T
Zentralbl Bakteriol; 1992 Jul; 277(2):204-9. PubMed ID: 1520979
[TBL] [Abstract][Full Text] [Related]
11. In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis.
Yamamoto T; Amitani R; Suzuki K; Tanaka E; Murayama T; Kuze F
Antimicrob Agents Chemother; 1996 Feb; 40(2):426-8. PubMed ID: 8834891
[TBL] [Abstract][Full Text] [Related]
12. Bacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages.
Mor N; Simon B; Heifets L
Antimicrob Agents Chemother; 1996 Jun; 40(6):1482-5. PubMed ID: 8726023
[TBL] [Abstract][Full Text] [Related]
13. Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Tomioka H; Sato K; Kajitani H; Akaki T; Shishido S
Antimicrob Agents Chemother; 2000 Feb; 44(2):283-6. PubMed ID: 10639351
[TBL] [Abstract][Full Text] [Related]
14. Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model.
Klemens SP; Grossi MA; Cynamon MH
Antimicrob Agents Chemother; 1994 Oct; 38(10):2245-8. PubMed ID: 7840552
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice.
Tomioka H; Saito H; Sato K; Yamane T; Yamashita K; Hosoe K; Fujii K; Hidaka T
Antimicrob Agents Chemother; 1992 Feb; 36(2):387-93. PubMed ID: 1605603
[TBL] [Abstract][Full Text] [Related]
16. [Therapeutic efficacy of a benzoxazinorifamycin, KRM-1648, in Mycobacterium intracellulare infection induced in mice].
Saito H; Tomioka H; Sato K; Hidaka T
Kekkaku; 1994 Feb; 69(2):59-63. PubMed ID: 8126989
[TBL] [Abstract][Full Text] [Related]
17. [In vivo activities of benzoxazinorifamycin KRM-1648, clarithromycin, and levofloxacin, or combination of KRM-1648 with diclofenac sodium against Mycobacterium avium infection induced in mice].
Akaki T; Sato K; Shimizu T; Tomioka H; Kawahara S
Kekkaku; 1997 Aug; 72(8):491-7. PubMed ID: 9293712
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial activities of benzoxazinorifamycin KRM-1648, clarithromycin and levofloxacin against intracellular Mycobacterium avium complex phagocytosed by murine peritoneal macrophages.
Sato K; Akaki T; Tomioka H
J Antimicrob Chemother; 1998 Jan; 41(1):77-83. PubMed ID: 9511040
[TBL] [Abstract][Full Text] [Related]
19. [In vitro antimicrobial activities of quinolones, rifamycins and macrolides against Mycobacterium tuberculosis and M.avium complex: attempt to establish new assay methods which accurately reflect therapeutic effects of test agents in vivo].
Sato K; Tomioka H
Kekkaku; 1999 Jan; 74(1):63-70. PubMed ID: 10067057
[TBL] [Abstract][Full Text] [Related]
20. [MICs and MBCs of levofloxacin, clarithromycin, and KRM-1648 for Mycobacterium tuberculosis and M. avium complex residing in MONO-MAC-6 human macrophage-like cell and A-549 human type II alveolar epithelial cell lines].
Sato K; Ogasawara K; Akaki T; Tomioka H
Kekkaku; 1999 Jul; 74(7):571-7. PubMed ID: 10481412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
